Intra- and extra-hospital improvement in ischemic stroke patients: influence of reperfusion therapy and molecular mechanisms

Sci Rep. 2020 Feb 26;10(1):3513. doi: 10.1038/s41598-020-60216-x.

Abstract

Neuroprotective treatments in ischemic stroke are focused to reduce the pernicious effect of excitotoxicity, oxidative stress and inflammation. However, those cellular and molecular mechanisms may also have beneficial effects, especially during the late stages of the ischemic stroke. The objective of this study was to investigate the relationship between the clinical improvement of ischemic stroke patients and the time-dependent excitotoxicity and inflammation. We included 4295 ischemic stroke patients in a retrospective study. The main outcomes were intra and extra-hospital improvement. High glutamate and IL-6 levels at 24 hours were associated with a worse intra-hospital improvement (OR:0.993, 95%CI: 0.990-0.996 and OR:0.990, 95%CI: 0.985-0.995). High glutamate and IL-6 levels at 24 hours were associated with better extra-hospital improvement (OR:1.13 95%CI, 1.07-1.12 and OR:1.14, 95%CI, 1.09-1.18). Effective reperfusion after recanalization showed the best clinical outcome. However, the long term recovery is less marked in patients with an effective reperfusion. The variations of glutamate and IL6 levels in the first 24 hours clearly showed a relationship between the molecular components of the ischemic cascade and the clinical outcome of patients. Our findings suggest that the rapid reperfusion after recanalization treatment blocks the molecular response to ischemia that is associated with restorative processes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Brain / diagnostic imaging
  • Female
  • Glutamic Acid / metabolism
  • Hospitals
  • Humans
  • Interleukin-6 / metabolism
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Odds Ratio
  • Reperfusion / methods*
  • Retrospective Studies
  • Stroke / pathology
  • Stroke / therapy*
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / therapeutic use
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Interleukin-6
  • Glutamic Acid
  • Tissue Plasminogen Activator